Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemia.
Panayiotidis P, Tumyan G, Thieblemont C, Ptushkin VV, Marin-Niebla A, García-Sanz R, Le Gouill S, Stathis A, Bottos A, Hamidi H, Katz P, Perretti T, Willis JC, Buske C. Panayiotidis P, et al. Among authors: ptushkin vv. Leuk Lymphoma. 2022 May;63(5):1058-1069. doi: 10.1080/10428194.2021.2015765. Epub 2022 Jan 19. Leuk Lymphoma. 2022. PMID: 35045765 Clinical Trial.
Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopenias.
Nikitin E, Kislova M, Morozov D, Belyakova V, Suvorova A, Sveshnikova J, Vyscub G, Matveeva I, Shirokova M, Shipaeva A, Klitochenko T, Makarovskaya P, Dmitrieva E, Biderman B, Sudarikov A, Obukhova T, Samoilova O, Kaplanov K, Konstantinova T, Mayorova O, Poddubnaya I, Ptushkin V. Nikitin E, et al. Leukemia. 2023 Jul;37(7):1464-1473. doi: 10.1038/s41375-023-01891-3. Epub 2023 May 18. Leukemia. 2023. PMID: 37202442 Free PMC article.
COVID-19 in patients with chronic lymphocytic leukemia: a Moscow observational study.
Kochneva ОL, Kislova M, Zhelnova EI, Petrenko AA, Baryakh EA, Yatskov KV, Dmitrieva EA, Misurina EN, Nikitin KE, Vasilieva EJ, Samsonova IV, Ptushkin VV, Baranova A, Nikitin EA. Kochneva ОL, et al. Among authors: ptushkin vv. Leuk Lymphoma. 2022 Jul;63(7):1607-1616. doi: 10.1080/10428194.2022.2034157. Epub 2022 Feb 13. Leuk Lymphoma. 2022. PMID: 35156528
[Five year experience in ibrutinib therapy for relapsed and refractory mantle cell lymphoma in real world Russian clinical practice].
Vorobyev VI, Gemdzhian EG, Fedorova LV, Mikhailova NB, Ilyasov RK, Kaleikina LP, Trubyakova OS, Kaplanov KD, Melnichenko EV, Martynova EV, Yakovleva EP, Li OY, Tarasenko EV, Chumakova EP, Bulieva NB, Nesterova ES, Margolin OV, Zherebtsova VA, Butaev LS, Ptushkin VV. Vorobyev VI, et al. Among authors: ptushkin vv. Ter Arkh. 2021 Jul 23;93(7):770-777. doi: 10.26442/00403660.2021.07.200930. Ter Arkh. 2021. PMID: 36286727 Russian.
Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia.
Cook G, Corso A, Streetly M, Mendeleeva LP, Ptushkin VV, Chan E, Ukropec J, Iraqi W, Al-Akabawi A, Pei H, Gaudig M, Petrucci MT, Alegre A, Mateos MV. Cook G, et al. Among authors: ptushkin vv. Oncol Ther. 2021 Jun;9(1):139-151. doi: 10.1007/s40487-020-00137-x. Epub 2021 Feb 25. Oncol Ther. 2021. PMID: 33630275 Free PMC article.
37 results